Track the RenovoRx, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, RenovoRx, Inc. has recorded 37 reports. Market capitalisation: €43.5m. The latest transaction was filed on 7 April 2026 (Attribution). Among the most active insiders: Agah Ramtin. All data is accessible without an account.
37
Insider Decl.
n/a
Thresholds
€190,707
30 ops.
Buy Volume
n/a
n/a
Sell Volume
59Σ signal
Buys €190,707n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,828 of 29,062 companies
26.4
score / 100
Value
9
Quality
44
FCF yld-25%
Earn yld-26%
EV/EBITDA·
ROE-100%
Gross mgn71%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
26,000 shares@ US$0.8429.1% of flowCommon StockSEC:0001641172-25-003364:0
Canonical exit: 7 Jul 2025 (T+90)
25 of 37 declarations
Acerca de RenovoRx, Inc.
RenovoRx, Inc. es una empresa centrada en el desarrollo de terapias dirigidas para el tratamiento del cáncer. Se especializa en la administración local de fármacos para mejorar la eficacia del tratamiento.